Get the Stockscreener App
432.22
1.65%
-7.23
After Hours:
432.22
Madrigal Pharmaceuticals Inc stock is traded at $432.22, with a volume of 190.64K.
It is down -1.65% in the last 24 hours and up +20.40% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$439.45
Open:
$439.99
24h Volume:
190.64K
Relative Volume:
0.51
Market Cap:
$9.60B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-17.21
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-0.15%
1M Performance:
+20.40%
6M Performance:
+32.05%
1Y Performance:
+84.11%
1-Day Range:
$426.17
$440.90
1-Week Range:
$425.00
$457.16
52-Week Range:
$200.63
$457.16
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
432.22 | 9.59B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Q3 Earnings Forecast for MDGL Issued By HC Wainwright - MarketBeat
Canaccord Genuity Boosts Madrigal Pharmaceuticals (MDGL) Price T - GuruFocus
Don't Ignore The Insider Selling In Madrigal Pharmaceuticals - simplywall.st
William John Sibold Sells 7,279 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Cinctive Capital Management LP Sells 4,315 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Woodline Partners LP Acquires 8,316 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 52-Week HighHere's What Happened - MarketBeat
CoreWeave and Madrigal’s Insider Trades Flash Bullish Signals - Investing.com
CoreWeave and Madrigal's Insider Trades Flash Bullish Signals - MarketBeat
Madrigal Pharmaceuticals Grants Equity Awards to New Employees - MSN
Madrigal Pharma CEO Sibold sells $3.24 million in stock By Investing.com - Investing.com Canada
Madrigal Pharma CEO Sibold sells $3.24 million in stock - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Now Covered by Analysts at HC Wainwright - MarketBeat
Can Madrigal Pharmaceuticals Inc. stock double in the next yearQuarterly Performance Summary & Free Expert Verified Stock Movement Alerts - Lancaster City Council
Can Madrigal Pharmaceuticals Inc. benefit from deglobalizationPortfolio Value Report & Short-Term High Return Ideas - Lancaster City Council
A Fresh Look at Madrigal Pharmaceuticals (MDGL) Valuation Following Recent Share Price Momentum - Yahoo Finance
Cutter Capital Management LP Invests $7.95 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 443.86 USD By Investing.com - Investing.com Canada
Published on: 2025-09-08 23:49:37 - beatles.ru
Madrigal Pharmaceuticals stock hits all-time high at 443.86 USD - Investing.com
Madrigal Pharmaceuticals to Present at Morgan Stanley Global Health Care Conference - MSN
Madrigal Pharmaceuticals Inc. Facing Inflection Point in Trend AnalysisWeekly Trade Report & Free Technical Confirmation Trade Alerts - beatles.ru
Adage Capital Partners GP L.L.C. Increases Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
MPM Bioimpact LLC Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
48,690 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Braidwell LP - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 52-Week HighTime to Buy? - MarketBeat
What is the PEG ratio of Madrigal Pharmaceuticals Inc.July 2025 Chart Watch & High Yield Stock Recommendations - خودرو بانک
Does Madrigal Pharmaceuticals Inc. have consistent dividend growthTrade Signal Summary & Risk Controlled Stock Alerts - خودرو بانک
Paulson & CO. Inc. Purchases 57,523 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Is Madrigal Pharmaceuticals Inc. a top pick in the sectorEarnings Performance Report & Accurate Technical Buy Alerts - خودرو بانک
What is the target price for Madrigal Pharmaceuticals Inc. stockWeekly Profit Report & AI Enhanced Execution Alerts - خودرو بانک
Will Madrigal Pharmaceuticals Inc. outperform the market in YEARJuly 2025 Final Week & Real-Time Chart Breakout Alerts - خودرو بانک
Published on: 2025-09-05 14:43:14 - Newser
How sentiment analysis helps forecast Madrigal Pharmaceuticals Inc.Weekly Risk Report & AI Forecast for Swing Trade Picks - Newser
Analyzing Madrigal Pharmaceuticals Inc. with risk reward ratio chartsQuarterly Portfolio Report & Long-Term Safe Return Strategies - Newser
How liquid is Madrigal Pharmaceuticals Inc. stock2025 Institutional Moves & AI Driven Stock Movement Reports - خودرو بانک
Is a relief rally coming for Madrigal Pharmaceuticals Inc. holdersMarket Performance Report & Verified Short-Term Trading Plans - Newser
Is Madrigal Pharmaceuticals Inc. stock trending bullishJuly 2025 Decliners & AI Powered Buy/Sell Recommendations - خودرو بانک
Published on: 2025-09-05 06:45:41 - Newser
Propel Bio Management LLC Has $9.95 Million Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Can machine learning forecast Madrigal Pharmaceuticals Inc. recoveryWeekly Stock Summary & AI Forecast Swing Trade Picks - Newser
What momentum shifts mean for Madrigal Pharmaceuticals Inc.Weekly Volume Report & Daily Price Action Insights - Newser
How sentiment analysis helps forecast Madrigal Pharmaceuticals IncEntry Point & Step-by-Step Swing Trade Plans - Newser
Analyzing net buyer seller activity in Madrigal Pharmaceuticals Inc.Portfolio Return Report & Step-by-Step Trade Execution Guides - Newser
Madrigal Pharmaceuticals Announces Grants of Inducement Awards u - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals' Rezdiffra Approval Sparks Higher Price Target from TD Cowen Analyst - AInvest
TD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval - Yahoo Finance
MDGL: HC Wainwright & Co. Assumes Buy Rating with $500 Target | - GuruFocus
Madrigal stock rating initiated at Buy by H.C. Wainwright with $500 target - Investing.com
Real time breakdown of Madrigal Pharmaceuticals Inc. stock performance2025 Market Overview & Technical Pattern Based Signals - Newser
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):